<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1054151198438221&amp;ev=PageView&amp;noscript=1">

It looks like your browser is incompatible with our website.

If you are currently using IE 11 or earlier, we recommend you update to the new Microsoft Edge or visit our site on another supported browser.

Challenges & Directions In Applying
Model-Based Drug Discovery & Development

Model-Informed Drug Discovery & Development (MID3) has been shown to be particularly useful in the drug development process and delivery of new therapies.

Using findings from the article Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives (CPT Pharmacometrics Syst. Pharmacol., 8: 87-96) as a reference point, a panel of up to three experts share their experience and insights surrounding model-based drug discovery and knowledge management.

They communicate recent advancements in methodology and explore what strides are necessary in order to achieve more predictable, cost-effective, and desired outcomes in the field of drug discovery and development.

Register now to watch on demand!

Sponsored by John Wiley & Sons, Inc. and Research Solutions, Inc. 


Priya Jayachandran, PharmD, MSE,

Associate Director, Pharmacometrician at Pfizer Inc.


Robert Radloff,

Director of Product Development at Research Solutions



Sharon Mattern Büttiker,

Director of Content Management at Research Solutions


Register Now